drug discovery
Repurposing drugs to manage COVID-19 progression
Researchers use large-scale human genetic studies to identify drug targets important for managing COVID-19 in its early…
Repurposing drugs for a pan-coronavirus treatment
Scientists from the Beltrao Group at EMBL-EBI and collaborators identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, three…
What COVID-19 is teaching us
The virtual EMBL Conference ‘SARS-CoV-2: Towards a New Era in Infection Research’ explored the importance of fundamental research, collaboration,…
Welcome: Ellie McDonagh
Open Targets welcomes new Informatics Science…
Understanding the influenza virus
The infectious disease commonly known as flu is caused by the influenza virus. It spreads around the world in seasonal outbreaks, causing millions of…
EMBL and Tara: Hamburg
EMBL Hamburg and Tara raise awareness of the risks of microplastic pollution and global…
Prioritising cancer drug targets using CRISPR
Large CRISPR screen prioritises hundreds of promising genes for personalised cancer…
New Open Targets Director appointed
New director drives drug discovery partnership…
Sanofi joins Open Targets
Pharmaceutical company Sanofi strengthens drug targets discovery collaboration Open…
Promega joins EMBL’s Corporate Partnership Programme
EMBL and Promega collaborate to train young…
Celgene joins Open Targets
New partner strengthens drug discovery…
Futures: Unravelling influenza
ERC grantee Stephen Cusack shares his vision for the next ten…
Last 6 months:
- April 2021 (15)
- March 2021 (17)
- February 2021 (23)
- January 2021 (17)
- December 2020 (18)
- November 2020 (12)
By year:
By topics:
- Alumni (101)
- Events (163)
- Lab Matters (400)
- Picture of the week (103)
- Science (707)
EMBLetc.
Read the latest Issues of our magazine - EMBLetc.
Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.
EMBLetc. archive